PORTSMOUTH, N.H., Jan. 6, 2026 /PRNewswire/ — Medispend and RLDatix Life Sciences today announced the successful completion of their merger, creating a unified PORTSMOUTH, N.H., Jan. 6, 2026 /PRNewswire/ — Medispend and RLDatix Life Sciences today announced the successful completion of their merger, creating a unified

Medispend and RLDatix Life Sciences Complete Merger, Uniting Under the Medispend Brand to Create The Leading Life Sciences Compliance Software-as-a-Service Provider

PORTSMOUTH, N.H., Jan. 6, 2026 /PRNewswire/ — Medispend and RLDatix Life Sciences today announced the successful completion of their merger, creating a unified organization that will operate under the Medispend name. The combined company offers a comprehensive suite of enterprise software and services for global regulatory and commercial compliance, medical affairs, field enablement and revenue management solutions designed to empower life sciences companies to grow their business compliantly.

While the company will continue under the Medispend name, the merger marks a significant evolution of the brand. Medispend is introducing a refreshed visual identity, including a new logo, color palette, and emblem, to reflect its expanded capabilities, forward-looking vision, and commitment to innovation.

The unified Medispend is positioned to become a single, trusted vendor providing the most comprehensive suite of life sciences compliance, stakeholder engagement, medical affairs, field enablement, and revenue management solutions in the industry. By combining the strengths of both organizations, Medispend now offers an expanded product portfolio supported by advanced technology, enhanced analytics, and scalable managed services designed to meet the evolving needs of global life sciences organizations.

“This merger represents a pivotal moment for our customers and the industry,” said Leigh Powell, executive chairman of Medispend. “By bringing together RLDatix Life Sciences and Medispend under one brand, we are accelerating our ability to deliver innovative, purpose-built solutions that help customers reduce risk, streamline operations, and confidently grow their business in an increasingly complex regulatory environment.”

Christopher Gingras, president of Medispend, said, “The new Medispend brand reflects a clear future vision, which includes our continued investment in innovative technology, expanded managed services, and a relentless focus on customer success.”

Existing customers will continue to receive uninterrupted service and support, while benefiting from the expanded capabilities and resources of the combined organization.

About Medispend:

Medispend is a global leading provider of SaaS solutions that deliver secure, scalable and intuitive cloud-based software enabling life sciences organizations to grow their business compliantly. More than 400 pharmaceutical, biotech and medical technology companies from around the world rely on Medispend to reduce compliance risk, improve customer engagements, optimize operations and make data driven decisions. Our mission is to help customers scale confidently and compliantly in an increasingly complex healthcare environment. For more information, visit www.medispend.com.

Media Contact:
Seth Houston
Chief Commercial Officer
shouston@medispend.com
(215) 779-2415

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/medispend-and-rldatix-life-sciences-complete-merger-uniting-under-the-medispend-brand-to-create-the-leading-life-sciences-compliance-software-as-a-service-provider-302652858.html

SOURCE Medispend

Market Opportunity
Cyberlife Logo
Cyberlife Price(LIFE)
$0.0274
$0.0274$0.0274
-1.08%
USD
Cyberlife (LIFE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Myriad Moves: Traders Bet on Zcash Rebound, But Aren't Buying Another Bitcoin All-Time High

Myriad Moves: Traders Bet on Zcash Rebound, But Aren't Buying Another Bitcoin All-Time High

Top markets on Myriad this week include predictions on a new Bitcoin all-time high, Ethereum’s next move, and whether Zcash will bounce back.
Share
Coinstats2026/01/09 05:17
Non-Consensual AI Nudes: Governments Confront the Alarming Grok-Generated Flood on X

Non-Consensual AI Nudes: Governments Confront the Alarming Grok-Generated Flood on X

BitcoinWorld Non-Consensual AI Nudes: Governments Confront the Alarming Grok-Generated Flood on X San Francisco, January 2025 – A disturbing technological phenomenon
Share
bitcoinworld2026/01/09 06:35
3 Paradoxes of Altcoin Season in September

3 Paradoxes of Altcoin Season in September

The post 3 Paradoxes of Altcoin Season in September appeared on BitcoinEthereumNews.com. Analyses and data indicate that the crypto market is experiencing its most active altcoin season since early 2025, with many altcoins outperforming Bitcoin. However, behind this excitement lies a paradox. Most retail investors remain uneasy as their portfolios show little to no profit. This article outlines the main reasons behind this situation. Altcoin Market Cap Rises but Dominance Shrinks Sponsored TradingView data shows that the TOTAL3 market cap (excluding BTC and ETH) reached a new high of over $1.1 trillion in September. Yet the share of OTHERS (excluding the top 10) has declined since 2022, now standing at just 8%. OTHERS Dominance And TOTAL3 Capitalization. Source: TradingView. In past cycles, such as 2017 and 2021, TOTAL3 and OTHERS.D rose together. That trend reflected capital flowing not only into large-cap altcoins but also into mid-cap and low-cap ones. The current divergence shows that capital is concentrated in stablecoins and a handful of top-10 altcoins such as SOL, XRP, BNB, DOG, HYPE, and LINK. Smaller altcoins receive far less liquidity, making it hard for their prices to return to levels where investors previously bought. This creates a situation where only a few win while most face losses. Retail investors also tend to diversify across many coins instead of adding size to top altcoins. That explains why many portfolios remain stagnant despite a broader market rally. Sponsored “Position sizing is everything. Many people hold 25–30 tokens at once. A 100x on a token that makes up only 1% of your portfolio won’t meaningfully change your life. It’s better to make a few high-conviction bets than to overdiversify,” analyst The DeFi Investor said. Altcoin Index Surges but Investor Sentiment Remains Cautious The Altcoin Season Index from Blockchain Center now stands at 80 points. This indicates that over 80% of the top 50 altcoins outperformed…
Share
BitcoinEthereumNews2025/09/18 01:43